Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? by Mutevedzi, Portia C et al.
Mutevedzi, PC; Lessells, RJ; Heller, T; Barnighausen, T; Cooke, GS;
Newell, ML (2010) Scale-up of a decentralized HIV treatment pro-
gramme in rural KwaZulu-Natal, South Africa: does rapid expansion
affect patient outcomes? Bulletin of the World Health Organization,
88 (8). pp. 593-600. ISSN 0042-9686
Downloaded from: http://researchonline.lshtm.ac.uk/2721/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.




Bull World Health Organ 2010;88:593–600 | doi:10.2471/BLT.09.069419
Introduction
South Africa is home to 5.7 million people living with human 
immunodeficiency virus (HIV) and acquired immunodeficiency 
syndrome (AIDS), or approximately 1 in 6 of the world’s HIV+ 
population.1 It also has the largest public-sector antiretroviral 
therapy (ART) programme in the world, with an estimated 
460 000 individuals established on ART by December 2007. 
However, as 1.5 million people living with HIV/AIDS in South 
Africa are estimated to be in need of ART, this figure only equates 
to 30% coverage.2 If the ambitious target set under the National 
Strategic Plan of universal access by 2011 is to be achieved, scale-
up of ART services must be intensified.3,4
There is good evidence that ART can be delivered effectively 
in South Africa, with individual virological and immunological 
responses to ART equivalent to those in high-resource settings.5 
Most published evidence relating to ART scale-up in South Af-
rica, however, has come from urban treatment cohorts or from 
provinces with primarily urban populations.5–9 Neighbouring 
countries in southern Africa have also reported programme out-
comes, although again based largely on urban cohorts.10,11 Only 
the Malawi national programme has reported large-scale data on 
a predominantly rural population.12 Delivery of HIV treatment 
and care to rural communities presents unique challenges, and 
current ART delivery models may significantly limit the acces-
sibility of ART.13 To have the greatest impact on public health, 
HIV treatment programmes will have to be decentralized and 
integrated into the existing primary health care system.14 Prelimi-
nary evidence from such rural programmes has demonstrated 
that ART provision in rural communities is feasible, given the 
appropriate resources and infrastructure.15,16
Concern has been raised that the rapid expansion of HIV 
services will reduce the quality of care for individuals within the 
programme as capacity and resources are stretched.17 Characteris-
tics of individuals accessing treatment may change over time, and 
this in itself may affect overall treatment outcomes.18 Monitoring 
treatment outcomes is essential to identify constraints or defi-
ciencies in programme performance, and viral load monitoring 
may provide warning of adherence problems and of possible 
development of acquired antiretroviral resistance.19
To evaluate a decentralized model of ART delivery in a 
rural community, we analysed the scale-up of our programme 
and explored trends in the characteristics of individuals accessing 
treatment and their outcomes within the first year of treatment.
Methods
Setting
The Hlabisa HIV Treatment and Care Programme is a partner-
ship between the local Department of Health and the Africa 
Centre for Health and Population Studies to deliver the South 
African Comprehensive HIV and AIDS Care, Management and 
Treatment Plan.20 It is a decentralized programme of HIV treat-
ment and care delivered through a network of 16 primary health 
Une traduction en français de ce résumé figure à la fin de l’article. Al final del artículo se facilita una traducción al español. .ةلاقلما هذهل لماكلا صنلا ةياهن في ةصلاخلا هذهل ةيبرعلا ةمجترلا
Objective To describe the scale-up of a decentralized HIV treatment programme delivered through the primary health care system in 
rural KwaZulu-Natal, South Africa, and to assess trends in baseline characteristics and outcomes in the study population.
Methods The programme started delivery of antiretroviral therapy (ART) in October 2004. Information on all patients initiated on ART 
was captured in the programme database and follow-up status was updated monthly. All adult patients (≥ 16 years) who initiated 
ART between October 2004 and September 2008 were included and stratified into 6-month groups. Clinical and sociodemographic 
characteristics were compared between the groups. Retention in care, mortality, loss to follow-up and virological outcomes were 
assessed at 12 months post-ART initiation.
Findings A total of 5719 adults initiated on ART were included (67.9% female). Median baseline CD4+ lymphocyte count was 116 
cells/µl (interquartile range, IQR: 53–173). There was an increase in the proportion of women who initiated ART while pregnant but 
no change in other baseline characteristics over time. Overall retention in care at 12 months was 84.0% (95% confidence interval, 
CI: 82.6–85.3); 10.9% died (95% CI: 9.8–12.0); 3.7% were lost to follow-up (95% CI: 3.0–4.4). Mortality was highest in the first 
3 months after ART initiation: 30.1 deaths per 100 person–years (95% CI: 26.3–34.5). At 12 months 23.0% had a detectable viral 
load (> 25 copies/ml) (95% CI: 19.5–25.5).
Conclusion Outcomes were not affected by rapid expansion of this decentralized HIV treatment programme. The relatively high rates 
of detectable viral load highlight the need for further efforts to improve the quality of services.
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care clinics in the Hlabisa subdistrict 
of Umkhanyakude district in northern 
KwaZulu-Natal. The subdistrict covers an 
area of 1430 km2 and has a population of 
approximately 220 000, mostly living in 
rural areas.21 HIV infection prevalence 
peaks at 50.9% among females aged 
25–29 years and 43.5% among males aged 
30–34 years.22 The programme employs a 
public health approach to ART delivery 
aimed at facilitating rapid scale-up of HIV 
treatment services.14,23 Support for the 
programme is provided by the President’s 
Emergency Plan for AIDS Relief (PEP-
FAR) through the United States Agency 
for International Development (USAID).
Patients
The programme adheres to the national 
antiretroviral treatment guidelines, which 
recommend initiation of ART for adults 
with stage IV disease as defined by the 
World Health Organization (WHO)24 
or a CD4+ lymphocyte (CD4 cell) count 
of < 200 cells/µl. 25 The first-line ART 
regimen consists of stavudine, lamivudine 
and either efavirenz or nevirapine. ART is 
initiated at primary health care clinics (or 
at Hlabisa hospital) by a physician after 
standard pre-ART evaluation and three 
treatment literacy sessions. Monitoring 
and ART dispensing are performed by 
nurses and counsellors at 2 weeks and 
4 weeks and then at 4-weekly intervals 
thereafter. CD4 cell count and HIV load 
are measured every 6 months.
Data acquisition
Longitudinal individual patient records 
are maintained at primary health care 
clinics. After initiation of ART, clinical 
and demographic information is trans-
ferred to a database developed and housed 
at the Africa Centre for Health and 
Population Studies (ART Evaluation and 
Monitoring Information System, or AR-
Temis), which is then updated monthly 
with follow-up status. Laboratory re-
sults (CD4 cell count and HIV load) 
are regularly imported into ARTemis. 
Demographic information is collected 
biannually and put into the Africa Centre 
Demographic Information System for 
approximately 90 000 individuals who 
are members of households within the 
Africa Centre Demographic Surveillance 
Area,26 which covers about one-third of 
the Hlabisa health subdistrict. Informa-
tion relating to socioeconomic status and 
household structure for individuals in 
ARTemis is therefore obtained through 
linkage of data sets, for all of which the 
patient’s national identity number is used. 
For these analyses, data were taken from 
the demographic surveillance period 
encompassing ± 9 months from the date 
of ART initiation.
Data analysis
Our analyses  included a l l  adults 
(≥ 16 years of age) who initiated ART 
within the programme between 1 Oc-
tober 2004 and 30 September 2008. 
Patients already on ART (504) who 
transferred into the programme were 
excluded. Patients were categorized into 
6-monthly groups on the basis of date 
of ART initiation and were stratified 
into four clinic groups: hospital-based 
(1 clinic); urban/periurban (2 clinics); 
large rural (≥ 200 patients on ART as 
of 30 September 2008 – 6 clinics); and 
small rural (< 200 patients on ART as of 
30 September 2008 – 7 clinics). We as-
sessed trends and differences in baseline 
characteristics across the 6-monthly and 
clinic strata on the basis of median tests 
and centile regression for continuous 
variables and proportions test and logistic 
regression for categorical variables. To 
assess possible selection bias associated 
with incomplete linkage of clinical and 
population data, we compared baseline 
and outcome variables between linked 
and unlinked individuals.
Outcomes (death, loss to follow-up 
and detectable viral load) at 12 months 
post-ART initiation were analysed for all 
patients who initiated ART up to 30 Sep-
tember 2007. Follow-up status was anal-
ysed at 12 months, whereas HIV load val-
ues were taken at 12 months ± 2 months 
to allow for variance in collection time 
points. HIV load was measured at a 
provincial laboratory using the Nucli-
Sens EasyQ® HIV-1 assay (bioMérieux 
sa, Marcy l’Etoile, France), with a lower 
detection limit of 25 copies/ml. Loss 
to follow-up was defined as having no 
clinic visit for 90 days or more. A total 
of 84 patients (2.8%) had only a baseline 
visit before being reported as deceased 
(n = 29), lost to follow-up (n = 38) or 
transferred out (n = 17). These patients 
were allocated 15 days of follow-up – the 
median time between the baseline visit 
and their next scheduled monthly clinic 
visit. Kaplan–Meier survival analysis was 
used to assess trends in time to death 
and detectable viral load and Cox regres-
sion to assess determinants of these two 
outcomes.
To account for substantial missing 
viral load data, independent baseline 
factors associated with missing data at 
12 ± 2 months post-ART were deter-
mined through logistic regression at a 
25% significance level. The resultant de-
terministic model was used to generate a 
propensity-to-be-missing score, defined as 
the probability for each patient of having 
a missing viral load reading.27,28 The Cox 
proportional hazard model for detectable 
viral load was controlled for the propen-
sity score as a re-weighting adjustment 
factor. Data were analysed using Stata 
version 10.0 (StataCorp, College Station, 
United States of America).
Ethical approval
Written informed consent was obtained 
from all patients in the programme to 
allow use of anonymous clinical data in 
research. Ethical approval was obtained 
from the Biomedical Research Ethics 
Committee of the University of KwaZu-
lu-Natal and the Research Office of the 
KwaZulu-Natal Department of Health 
for linkage and use of these data.
Results
Patients
A total of 5719 adult patients were initi-
ated on ART in the programme between 
1 October 2004 and 30 September 2008 
(Fig. 1); 2509 patients (43.9%) reported a 
physical address within the demographic 
surveillance area at the time of ART 
initiation and hence were eligible for 
linkage, and 1804 (72%) of them were 
successfully linked.
Despite a 10-fold increase in the 
number of patients initiating ART 
(Table 1), the health worker-to-patient ra-
tio only declined by 0.5, as staff increased 
from 6 in the first half-year of analysis to 
99 in the last half–year. The most rapid 
growth occurred in large rural clinics as 
decentralization progressed (Fig. 2).
Baseline characteristics
Females (3883) made up 67.9% of all 
patients initiated on ART, with no 
significant differences in proportion of 
females between clinic groups. Males 
initiated at a higher median age (37 
years, interquartile range, IQR: 32–45) 
than females (34 years, IQR: 28–41) 
(P < 0.001) and had a lower median 
CD4 cell count at initiation (91 cells/µl, 
IQR: 41–156) than females (128 cells/
µl, IQR: 66–179) (P < 0.001). A higher 
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proportion of males (29.6%) than females 
(18.2%) (P < 0.001) initiated with a CD4 
cell count < 50 cells/µl (P < 0.001). Preva-
lent tuberculosis at initiation was more 
common in males (20.4%) than females 
(15.6%) (P < 0.001).
There were no significant differences 
across clinic groups, except for the median 
CD4 cell count, which was significantly 
lower at the hospital clinic (99 cells/µl) 
than at the urban/peri-urban (114 cells/
µl; P = 0.032), large rural (128 cells/µl; 
P < 0.001), and small rural clinics (117.5 
cells/µl; P = 0.023).
Table 1 shows overall baseline char-
acteristics and trends over time.
Outcomes
People who initiated treatment between 
October 2007 and September 2008 
(2709) were excluded, leaving 3010 
patients for outcomes analysis. Overall 
retention at 12 months was 84.0% (95% 
confidence interval, CI: 82.6–85.3) and 
mortality was 10.9% (95% CI: 9.8–12.0). 
The proportion with a detectable viral 
load declined but remained high at 
around 23%. Table 2 shows overall out-
comes, including trends over time.
At 12 months post-initiation, the 
3010 patients had accumulated 2617 
person-years of follow-up, with 329 
deaths: a mortality rate of 12.6 deaths per 
100 person-years (95% CI: 11.3–14.0). 
The mortality rate peaked in the first 
3 months following ART initiation at 
30.1 deaths per 100 person-years (95% 
CI: 26.3–34.5) and fell thereafter to 6.2 
deaths per 100 person-years (95% CI: 
5.2–7.4). Male gender, lower weight, 
CD4 cell count < 50cells/µl, low haemo-
globin, high creatinine and lack of formal 
education were significantly associated 
with mortality (Table 3). Univariably, 
initiation outside the hospital clinic was 
associated with lower mortality (with ref-
erence to the hospital clinic, hazard ratio, 
HR: 0.49, 0.62 and 0.51 for urban, small 
rural and large rural clinics, respectively; 
P < 0.01), but significance was not main-
tained when we adjusted for time period. 
There were no statistically significant 
differences between people with missing 
values and the reference group for the 
respective variables (Table 3).
Of 2527 people recorded as ac-
tive 12 months post-initiation, 758 
(30.0%) had a viral load result recorded at 
12 ± 2 months following ART initiation, 
and 174 of those 758 patients (23.0%; 
95% CI: 19.5–25.5) had detectable viral 
loads (≥ 25 copies/ml). The propensity 
to be missing decreased from a median 
probability of 0.96 in the first half-year to 
0.52 in the final half-year (P < 0.001). The 
hazard of having a detectable viral load 
was 2.8 (95% CI: 1.05–7.85) in the last 
three half-year periods compared to the 
three preceding periods. This increased 
risk lost statistical significance after we 
adjusted for the propensity score. We 
found no factors that were significantly 
associated with having a detectable viral 
load in the multivariable model.
Comparison of data
The proportion of patients who died was 
11.3% in the unlinked group versus 10.3% 
in the linked group (P = 0.347). The pro-
portion retained was 83.5% versus 84.8% 
(P = 0.423) in the unlinked and linked 
groups, respectively, and the proportion 
with a detectable viral load was 22.9% 
versus 23.0% (P = 0.987). Although the 
proportion of females in the unlinked 
group (66.4%) was slightly lower than 
in the linked group (71.1%) (P < 0.001), 
there were no significant differences in 
other baseline characteristics: CD4 cell 
count and proportion with CD4 cell 
count < 50cells/µl, blood creatinine, 
blood haemoglobin, weight and age.
Discussion
To meet targets of universal access to 
ART, efforts to scale up HIV treatment 
programmes in South Africa need to 
be intensified. The treatment model de-
scribed here, a decentralized programme 
with treatment delivered through the 
primary health-care system, has allowed 
rapid scale-up, with 5719 adult patients 
initiated on ART in a 4-year period. The 
rapid growth in rural clinics is encourag-
ing and suggests that the availability of 
care at the local level reduces the common 
barriers (travel time and cost) to ART 
uptake. Success in scale-up may be partly 
attributed to growth in the programme’s 
financial and human resources, which 
increased by about 20-fold in the first 
4 years as a result of PEPFAR support. 
Notwithstanding all efforts to scale up 
financial and human resources, most of 
the programme emphasis has been on 
initiating patients onto treatment. Other 
aspects of HIV care, such as pre-ART 
monitoring and long-term adherence 
support, have received less emphasis so 
far, but these will become more important 
as programmes mature, and additional 
resources will be required to maintain 
delivery of high-quality care. 
Sustaining such programmes requires 
significant inputs of human and financial 
resources, and it may not be feasible to 
maintain steep increases. However, at 
some point a steady-state will likely be 
reached, and resources can then be fo-
cused on sustaining the programme. Task-
shifting and reducing the number of times 
patients attend clinics for drug collection 
may enhance programme sustainability. 
Fig. 1. Cumulative number of patients initiating antiretroviral therapy between 
October 2004 and September 2008 in a decentralized HIV treatment 
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HIV, human immunodeficiency virus.
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Further integration of primary health 
care systems and HIV treatment and 
care delivery services will also facilitate 
programme continuity. 
The characteristics of individuals 
accessing ART through the programme 
have changed little over time. Unlike the 
situation in other programmes in South 
Africa that started before the national 
roll-out of ART5–7, the median baseline 
CD4 cell count of patients served by 
our programme has remained relatively 
high since inception in 2004, although 
it is similar to that reported for other 
programmes in sub-Saharan Africa in 
2005–2006.18 A high proportion of 
patients continue to start treatment 
with very advanced disease: 1 in 3 male 
patients have CD4 cell counts of < 50 
cells/µl when they initiate ART. The 
higher proportion and younger age of 
females in the programme are consistent 
with local prevalence data and with other 
cohorts in South Africa.5–7,22 However, 
the difference in median baseline CD4 
cell count between females and males (37 
cells/µl) is even greater than the mean dif-
ference reported for other sub-Saharan 
Africa programmes participating in the 
Antiretroviral Therapy in Lower Income 
Countries (ART-LINC) Collaboration 
(22 cells/µl).18 The finding that male sex 
was also independently associated with 
mortality highlights the need for strate-
gies to engage men in HIV care before the 
onset of advanced disease.
The overall mortality rate in our 
programme (12.6 deaths per 100 per-
son–years) is high but still comparable 
to the rates found in other cohorts in 
southern Africa.8,29–32 Most deaths occur 
in the first 3 months after ART initia-
tion, as seen in other cohorts, largely as a 
result of people presenting with late-stage 
disease, although our rate of 30.1 deaths 
per 100 person–years during the first 
3 months of ART is much higher than 
reported elsewhere. The contribution 
of immune reconstitution inflamma-
tory syndrome (IRIS) and/or the lack of 
routine physician follow-up to this early 
mortality cannot be ascertained from 
our data. Linkage with our demographic 
surveillance data has revealed that lack 
of education is significantly associated 
with death among patients on ART. This 
relationship has been described elsewhere 
and may indicate a group that requires 
enhanced support both before and after 
initiating ART.33
We show relatively low rates of loss to 
follow-up. This is likely explained in part 
by the active tracking system within the 
programme, which includes phone contact 
by clinic staff, followed, if necessary, by a 
home visit from a tracker nurse. Our figures 
for mortality and loss to follow-up might 
thus reflect the true situation better than 
those from other programmes in which pa-
tients are not actively tracked and where up 
to half of those lost to follow-up may have 
died.34,35 It is possible that the decentralized 
model, with treatment provided closer to 
patients’ homes, also contributes to this 
low rate of loss to follow-up. It is encour-
aging that there is no sign of a consistent 
increase in loss to follow-up rates despite 
the rapid scale-up of the programme.
One troubling aspect of our data is the 
relatively high rate of detectable viral load 
among patients on ART. There were many 
missing results, which is likely to be related 
to several factors: samples not taken at ap-
propriate time points, results not returned 
from the provincial reference laboratory 
and faults in data capture. However, by 
using propensity score reweighting, we 
have shown that almost 1 in 4 people on 
ART had a detectable viral load at around 
12 months. We used a strict cut-off (< 25 
copies/ml), as we believe that this will alert 
us to deficiencies within the programme, 
although this approach makes comparison 
with other programmes using different 
criteria difficult. Primary drug resistance 
should not be a significant factor in lack of 
virological suppression, as levels of primary 
resistance were low in our setting at the 
time of the analysis.36 There have been no 
significant stock-outs of ART in our pro-
gramme, and the high rate of unsuppressed 
viral load may therefore suggest suboptimal 
adherence. We are researching this ques-
tion in more detail and are learning how 
to translate successful models of adherence 
support from neighbouring programmes.37
The similarity between the unlinked 
and linked groups is as expected, given 
that most of the lack of linkage in those 
eligible arose as a result of typographi-
cal errors in entering identity numbers 
into patient records, failure to match the 
identity number to other personal identi-
fiers, or the fact that patients presented at 
clinics without identity documents. Since 
these occurrences probably occurred 
at similar rates in all groups, we do not 
believe they influenced outcomes or their 
associated factors.
Our study had certain limitations. 
Data collected from routine programme 
evaluation are limited by operational 
constraints that might not hamper for-
mal research cohorts. Our description of 
scale-up and outcomes is limited by a lack 
of information on individuals enrolled 
in the programme but not initiated on 
ART. Data from other programmes sug-
gest that mortality is extremely high in 
the period after enrolment but before 
initiation of ART.29,30 It would be ex-
tremely useful to evaluate whether our 
decentralized model based on primary 
health care improves access to treatment 
and reduces pre-initiation mortality but 
increases early post-initiation mortality. 
By exploring outcomes at 12 months only 
we may have missed trends in longer-term 
outcomes, particularly retention and viral 
suppression.
Fig. 2. Number of patients initiated on antiretroviral therapy from October 2004 to 
September 2008 in a decentralized HIV treatment programme in rural KwaZulu-
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صخللما
 لىع عيسرلا عسوتلا رثوي له :ايقيرفأ بونج في ،لاتان ولوزاوك فير في زديلإا سويرفب ينباصملل ةيزكرملالا ةجلاعلماب ءاقترلاا جمانرب
؟ضىرلما جئاتن
In summary, we have shown that 
rapid scale-up of ART delivery through 
a decentralized primary health care 
programme is feasible and produces 
outcomes comparable to those reported 
elsewhere in southern Africa. The rela-
tively high rates of detectable viral load 
in patients on ART are troubling, and 
further scale-up poses significant chal-
lenges and will require considerable 
commitment if we are to reach the goal 
of universal access. ■
Acknowledgements
We would like to thank Colin Newell for 
development of and assistance with the 
database, Samukelisiwe Dube for assis-
tance with data-cleaning, the monitoring 
and evaluation team at the Africa Centre 
for data collection, and the Department 
of Health. We would particularly like to 
thank all the clinic staff whose dedicated 
work in the face of so many challenges is 
an inspiration to us all.
Funding: The HIV treatment and care 
programme has received generous sup-
port from the United States Agency for 
International Development (USAID) 
and the President’s Emergency Plan for 
AIDS Relief (PEPFAR) under the terms 
of award no. 674-A-00-08-0001-00. The 
opinions expressed herein are those of 
the authors and do not necessarily re-
flect the views of USAID or the United 
States Government. Tom Heller and 
Till Bärnighausen are supported by the 
Centre for International Migration and 
Development, Gesellschaft für Tech-
nische Zusammenarbeit (GTZ), Federal 
Ministry of Economic Cooperation and 
Development, Germany. The Africa Cen-
tre is supported by a core grant from the 
Wellcome Trust.
Competing interests:  None declared.
 زديلإا سويرفب ينباصملل ةيزكرملالا ةجلاعلماب ءاقترلاا جمانرب فْصو ضرغلا
 نم ةيفيرلا قطانلما في ةيلولأا ةيحصلا ةياعرلا ماظن للاخ نم مدقُي يذلاو
 في جئاتنلاو ةيدعاقلا تافصلا تاهاجتا مييقتو ،ايقيرفأ بونجب لاتان ولوزاوك
.ةساردلل تعضخ يتلا ةيناكسلا ةرهمجلا
 نيشرت في ةيرقهقلا تاسويرفلا تاداضبم ةجلاعلما ميدقت في جمانبرلا أدب قرطلا
 عيمجب  ةصاخلا  تامولعلما  ةفاك  تلخدأ  دقو  .2004  ماع  نم  ربوتكأ/لولأا
 ناكو ،جمانبرلاب ةصاخلا تانايبلا ةدعاق في ةجلاعلما هذه اولهتسا نيذلا ضىرلما
 في لخدأ دقو .ةعباتلما نع ةمجانلا ةظحلالما عاضولأاب ًايرهش اهثيدحت يرجي
 ةجلاعلما اوأدب نيذلا )اماع 16≤( ينغلابلا ضىرلما عيمج هذه تانايبلا ةدعاق
 مهبيترت  متو  ،2008  برمتبس/لوليأ  و  2004  ربوتكأ/لولأا  نيشرت  ينب  ام  في
 تماسلل تانراقم تيرجأو .رهشأ ةتس ةدلم ةساردلل عضخت تاعومجم لىإ
 ءاقبتسا مييقت مت ماك ،تاعومجلما هذه ينب ةيناكسلاو ةيعماتجلااو ةيريسرلا
Table 3. Risk factors for death within 12 months in patients initiated on antiretroviral 
therapy from October 2004 to September 2007 in a decentralized HIV 
treatment programme in rural KwaZulu-Natal, South Africa
Variable HR 95% CI AHR 95% CI
Sex
Male 1.62 1.49–1.77 1.33 1.06–1.67
Weighta
1-kg increase 0.95 0.94–0.96 0.96 0.94–0.99
CD4 count (cells/µl)
> 200 1
150–200 0.74 0.44–1.24 0.70 0.42–1.16
100–149 1.02 0.63–1.67 0.84 0.52–1.36
50–99 1.82 1.16–2.86 1.42 0.91–2.21
< 50 3.17 2.08–4.84 2.02 1.33–3.08
Missing 1.20 0.69–2.06 0.92 0.53–1.60
WHO clinical stageb
1 or 2 1
3 or 4 3.25 1.98–5.34 2.13 1.29–3.51
Missing 1.68 1.01–2.82 1.44 0.86–2.42
Haemoglobin (g/dL)
≥ 8 1
< 8 4.10 3.12–5.37 2.72 2.03–3.63
Missing 1.31 0.96–1.77 1.04 0.67–1.59
Creatinine (μmol/L)
≤ 120 1
121–240 2.72 1.86–3.98 1.66 1.13–2.44
> 240 9.24 4.74–17.99 2.88 1.42–5.81
Missing 1.27 0.93–1.73 1.28 0.84–1.97
Education
Secondary 1
Primary 1.36 0.84–2.20 1.14 0.71–1.86
None 1.74 1.05–2.87 1.81 1.10–2.99
Missing 0.78 0.35–1.75 0.63 0.28–1.50
Not matched 1.39 0.99–1.94 1.30 0.93–1.83
Half-year of initiation
Oct 04–Mar 05 1
Apr 05–Sep 05 0.40 0.22–0.72 0.39 0.21–0.70
Oct 05–Mar 06 0.56 0.35–0.88 0.53 0.33–0.84
Apr 06–Sep 06 0.40 0.25–0.65 0.46 0.28–0.75
Oct 06–Mar 07 0.57 0.37–0.90 0.53 0.34–0.83
Apr 07–Sep 07 0.61 0.40–0.93 0.61 0.40–0.95
AHR, adjusted hazards ratio; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazards ratio.
a Weight assessed as a time-varying covariate.
b Staging category at time of ART initiation in accordance with WHO staging criteria.24
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 كلذو ةيسويرفلا جئاتنلاو ،ةعباتلما نع مهبايغو ،تايفولاو ،ةياعرلا في تلااحلا
 .ةيرقهقلا تاسويرفلا تاداضبم ةجلاعلما ءدب نم ارهش 12 رورم دعب
 ةجلاعلما اوأدب ًاغلاب 5719 غلب ليماجإ ددع لىع ةساردلا تلمتشا تادوجولما
 يدعاقلا طخلا ناكو .)ًاثانإ نك مهنم 67.9%( ةيرقهقلا تاسويرفلا تاداضبم
 ناكو( ترلوركم لكل ةيلخ 116 وه CD4+ ةيوافملل ايلاخلا دادعتل يطسولا
 ةبسن في ةدايز كانه تناكو . .)173 - 53 :ينتييعبرلا ينتحيشرلا ينب ىدلما
 لمو ،لماوح نكو ةيرقهقلا تاسويرفلا تاداضبم ةجلاعلما نأدب ئيلالا ءاسنلا
 تناكو  .تقولا  رورم  عم  ىرخلأا  ةيدعاقلا  تافصلا  لىع  تايرغت  ةيأ  أرطت
 :95%  ةقث  ةلصاف(  84.0%  ،ارهش  12  ةدلم  ةياعرلا  تحت  ءاقبتسلاا  ةبسن
 ،)12.0-9.8 :95% ةقثلا ةلصاف( 10.9% تغلب تايفو ةبسن عم ؛)85.3-82.6
 تايفولا  تناكو  .)4.4-3.0  :95%  ةقثلا  ةلصاف(  ةعباتلما  نع  3.7%  باغو
 تاسويرفلا تاداضبم ةجلاعلما ءدب تلت يتلا لىولأا رهشأ ةثلاثلا للاخ ثركأ
 :95% ةقثلا ةلصاف( دحاولا ماعلا في ضيرم ةئم لكل ةافو 30.1 :ةيرقهقلا
 ءبعلا نم 23.0% تغلب ةبسن تفشتكا شرع نياثلا رهشلا فيو .)34.5-26.3
.)25.5-19.5 :95% ةقثلا ةلصاف( )ترليلم لكل ةخسن 25 نم ثركأ( سيويرفلا
 ةيزكرملا لىإ فداهلا جمانبرلا اذهل عيسرلا عسوتلاب جئاتنلا رثأتت لم جاتنتسلاا
 ءبعلا  نم  ةفشتكلما  ًايبسن  ةيلاعلا  تلادعلما  امأ  ،زديلإا  سويرف  ةجلاعم
 ةدوج  ينسحتل  دوهجلا  نم  ديزلما  لذب  لىإ  ةجاحلا  تحضوأف  سيويرفلا
.تامدخلا
Objectif Décrire le passage à l’échelle supérieure d’un programme 
décentralisé de traitement du VIH délivré au travers du système de soins 
de santé primaires au KwaZulu-Natal rural, Afrique du Sud, et évaluer 
les tendances des caractéristiques de ligne de base et les résultats sur 
la population étudiée. 
Méthodes Le programme a commencé la distribution d’une thérapie 
antirétrovirale (TAR) en octobre 2004. Les informations concernant 
l’ensemble des patients entamant un traitement TAR ont été recueillies 
dans une base de données informatisée et le suivi de leur état a été 
actualisé chaque mois. Tous les patients adultes (≥ 16 ans) ayant 
commencé la TAR entre octobre 2004 et septembre 2008 ont été inclus 
et stratifiés en groupes de 6 mois. Les caractéristiques cliniques et 
sociodémographiques ont été comparées entre les groupes. Les taux 
de rétention sous traitement et de mortalité, ainsi que les nombres de 
perdus pour le suivi et les résultats virologiques ont été évalués 12 mois 
après le début de la TAR.
Résultats Au total 5 719 patients ayant initié un traitement TAR ont été 
inclus (67,9 % de femmes). Le nombre moyen de lymphocytes CD4+ 
à la ligne de base était de 116 cellules/µL (intervalle interquartile, IQR: 
53-173). Une augmentation de la proportion de femmes ayant entamé un 
traitement TAR alors qu’elles étaient enceintes a été notée, mais aucun 
changement n’a été observé dans le temps pour les autres caractéristiques 
à la ligne de base. Le taux global de rétention sous traitement à 12 mois 
était de 84,0 % (intervalle de confiance à 95 %, IC: 82,6-85,3); 10,9 % 
sont décédés (IC à 95 %: 9,8-12,0); 3.7 % ont été perdus pour le suivi 
(IC à 95 %: 3,0-4,4). La mortalité a été plus élevée durant les 3 premiers 
mois qui ont suivi le début de TAR : 30,1 décès pour 100 personnes-ans 
(IC à 95 %: 26,3-34,5). À 12 mois, 23,0 % présentaient une charge virale 
détectable (> 25 copies/ml) (IC à 95 %: 19,5-25,5).
Conclusion Les résultats n’ont pas été affectés par la rapide expansion 
de ce programme de traitement du VIH décentralisé. Les taux relativement 
élevés de charge virale détectable mettent en évidence la nécessité de 
futurs efforts à mettre en place pour améliorer la qualité des services.
Résumé
Mise en place élargie d’un programme décentralisé de traitement du VIH dans le KwaZulu-Natal rural, Afrique 
du Sud : une expansion rapide affecte-elle les résultats des patients?
Resumen
Ampliación de un programa descentralizado de tratamiento del VIH en zones rurales de KwaZulu-Natal, 
Sudáfrica: ¿afecta su rápida expansión a los resultados de pacientes?
Objetivos Describir la ampliación de un programa descentralizado de 
tratamiento del VIH a través del sistema sanitario de atención primaria 
en zonas rurales de KwaZulu-Natal, Sudáfrica, y evaluar las tendencias 
de las características iniciales y los resultados de la población en estudio.
Métodos El programa comenzó con la administración de un tratamiento 
antirretroviral (ARV) en octubre de 2004. La información de todos los 
pacientes que comenzaron el tratamiento ARV se recopiló en la base de 
datos del programa y el seguimiento se actualizó mensualmente. Todos 
los pacientes adultos (≥ 16 años) que iniciaron el tratamiento ARV entre 
octubre de 2004 y septiembre de 2008 se incluyeron y estratificaron 
en grupos de seis meses. Se compararon las características clínicas y 
sociodemográficas intergrupales. A los 12 meses del inicio del tratamiento 
ARV se evaluó la continuidad asistencial, la pérdida para el seguimiento 
y los resultados virológicos.
Resultados Se incluyó a un total de 5719 adultos que habían iniciado el 
tratamiento ARV, de los que el 67,9% eran mujeres. El recuento medio 
inicial de linfocitos CD4 fue de 116 células/µl (amplitud intercuartil, AIC: 
53 - 173). El porcentaje de mujeres que iniciaron el tratamiento ARV 
durante el embarazo aumentó, si bien no se produjo ningún cambio 
en otras características iniciales a lo largo del tiempo. La continuidad 
asistencial general a los 12 meses fue del 84,0% (intervalo de confianza 
del 95%, CI: 82; 6 - 85,3); el 10,9% falleció (CI del 95%: 9; 8 - 12,0); el 
3,7% se perdió para el seguimiento (CI del 95%: 3,0 - 4,4). La mortalidad 
fue más elevada en los primeros tres meses posteriores al inicio del 
tratamiento ARV: 30,1 fallecimientos por cada 100 años-personas (CI 
del 95%: 26,3 - 34,5). El 23,0% tenía una carga viral detectable a los 
12 meses (> 25 réplicas/ml) (CI del 95%: 19,5 - 25,5).
Conclusión Los resultados no se vieron afectados por la rápida expansión 
de este programa descentralizado de tratamiento del VIH. Los índices 
relativamente altos de la carga vírica detectable ponen en evidencia la 
necesidad de dedicar un mayor esfuerzo en la mejora de la calidad de 
los servicios.
Bull World Health Organ 2010;88:593–600 | doi:10.2471/BLT.09.069419600
Portia C Mutevedzi et al.Outcomes of HIV programme in rural South Africa
Research
References
1. Report on the global HIV/AIDS epidemic 2008. Geneva: Joint United Nations 
Programme on HIV/AIDS; 2008.
2. Towards universal access: scaling up priority HIV/AIDS interventions in the 
health sector. Geneva: World Health Organization; 2008.
3. HIV & AIDS and STI national strategic plan 2007–2011. Pretoria: South 
African Department of Health; 2007.
4. Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana 
MO et al. Scaling up antiretroviral therapy in South Africa: the impact of 
speed on survival. J Infect Dis 2008;197:1324–32. doi:10.1086/587184 
PMID:18422445
5. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, Furrer H et al. Public-
health and individual approaches to antiretroviral therapy: township South 
Africa and Switzerland compared. PLoS Med 2008;5:e148. doi:10.1371/
journal.pmed.0050148 PMID:18613745
6. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a 
community-based HIV treatment service: programme performance over 3 
consecutive years in Guguletu, South Africa. S Afr Med J 2006;96:315–20. 
PMID:16670804
7. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V et al. 
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, 
South Africa. AIDS 2004;18:887–95. doi:10.1097/00002030-200404090-
00006 PMID:15060436
8. Boulle A, Bock P, Osler M, Cohen K, Channing L, Hilderbrand K et al. 
Antiretroviral therapy and early mortality in South Africa. Bull World Health 
Organ 2008;86:678–87. doi:10.2471/BLT.07.045294 PMID:18797643
9. Fairall LR, Bachmann MO, Louqagie GM, van Vuuren C, Chikobvu P, 
Steyn D et al. Effectiveness of antiretroviral treatment in a South African 
program: a cohort study. Arch Intern Med 2008;168:86–93. doi:10.1001/
archinternmed.2007.10 PMID:18195200
10. Stringer JSA, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH et al. Rapid 
scale-up of antiretroviral therapy at primary care sites in Zambia. Feasibility 
and early outcomes. JAMA 2006;296:782–93. doi:10.1001/jama.296.7.782 
PMID:16905784
11. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, 
Puvimanasinghe J et al. Five-year outcomes of initial patients treated in 
Botswana’s national antiretroviral treatment program. AIDS 2008;22:2303–
11. doi:10.1097/QAD.0b013e3283129db0 PMID:18981769
12. Lowrance DW, Makombe S, Harries AD, Shiraishi RW, Hochgesang M, Aberle-
Grasse J et al. A public health approach to rapid scale-up of antiretroviral 
treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr 
2008;49:287–93. doi:10.1097/QAI.0b013e3181893ef0 PMID:18845953
13. Wilson DP, Blower S. How far will we need to go to reach HIV-infected people 
in rural South Africa? BMC Med 2007;5:16. doi:10.1186/1741-7015-5-16 
PMID:17577418
14. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y et al. The 
WHO public-health approach to antiretroviral treatment against HIV in 
resource-limited settings. Lancet 2006;368:505–10. doi:10.1016/S0140-
6736(06)69158-7 PMID:16890837
15. Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral 
therapy in rural communities: the Lusikisiki model of decentralized HIV/
AIDS care. J Infect Dis 2007;196(Suppl 3):S464–8. doi:10.1086/521114 
PMID:18181695
16. Fredlund VG, Nash J. How far should they walk? Increasing antiretroviral 
therapy access in a rural community in northern KwaZulu-Natal, South 
Africa. J Infect Dis 2007;196(Suppl 3):S469–73. doi:10.1086/521115 
PMID:18181696
17. Boulle A, Ford N. Scaling up antiretroviral therapy in developing countries: 
what are the benefits and challenges? Postgrad Med J 2008;84:225–7. 
doi:10.1136/sti.2007.027748 PMID:18508978
18. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A et al. 
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient 
characteristics, treatment regiments and monitoring in sub-Saharan 
Africa, Asia and Latin America. Trop Med Int Health 2008;13:870–9. 
PMID:18373510
19. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E et al. HIV viral 
load monitoring in resource-limited regions: optional or necessary? Clin Infect 
Dis 2007;44:128–34. doi:10.1086/510073 PMID:17143828
20. Operational plan for comprehensive HIV and AIDS care, management and 
treatment for South Africa. Pretoria: South African Department of Health; 
2003.
21. Tanser F. Methodology for optimising location of new primary health care 
facilities in rural communities: a case study in KwaZulu-Natal, South 
Africa. J Epidemiol Community Health 2006;60:846–50. doi:10.1136/
jech.2005.043265 PMID:16973529
22. Welz T, Hosegood V, Jaffar S, Bätzing-Feigenbaum J, Herbst K, Newell ML. 
Continued very high prevalence of HIV infection in rural KwaZulu-Natal, 
South Africa: a population-based longitudinal study. AIDS 2007;21:1467–72. 
doi:10.1097/QAD.0b013e3280ef6af2 PMID:17589193
23. Antiretroviral therapy for HIV infection in adults and adolescents: 
recommendations for a public health approach, 2006 revision. Geneva: World 
Health Organization; 2006.
24. WHO case definitions of HIV for surveillance and revised clinical staging and 
immunological classification of HIV-related disease in adults and children. 
Geneva: World Health Organization; 2007.
25. National antiretroviral treatment guidelines. Pretoria: South African 
Department of Health; 2004.
26. Tanser F, Hosegood V, Bärnighausen T, Herbst K, Nyirenda M, Muhwava 
W et al. Cohort profile: Africa Centre Demographic Information System 
(ACDIS) and population-based HIV survey. Int J Epidemiol 2008;37:956–62. 
doi:10.1093/ije/dym211 PMID:17998242
27. Baker SG, Fitzmaurice GM, Freedman LS, Kramer BS. Simple adjustments for 
randomized trials with nonrandomly missing or censored outcomes arising 
from informative covariates. Biostatistics 2006;7:29–40. doi:10.1093/
biostatistics/kxi038 PMID:15923407
28. Moss RR, Humphries KH, Gao M, Thompson CR, Abel JG, Fradet G et al. 
Outcome of mitral valve repair or replacement: a comparison by propensity 
score analysis. Circulation 2003;108(Suppl 1):II-90–7. PMID:12970215 
doi:10.1161/01.cir.0000089182.44963.bb
29. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among 
adults accessing a community-based antiretroviral service in South Africa: 
implications for programme design. AIDS 2005;19:2141–8. doi:10.1097/01.
aids.0000194802.89540.e1 PMID:16284464
30. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of 
mortality and nondeath losses from an antiretroviral treatment service in 
South Africa: implications for program evaluation. AIDS 2006;43:770–6. 
PMID: 16912954doi:10.1086/507095.
31. Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, Miotti P et al. 
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: 
comparison between low-income and high-income countries. Lancet 
2006;367:817–24. doi:10.1016/S0140-6736(06)68337-2 PMID:16530575
32. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among 
adults accessing antiretroviral treatment programmes in sub-Saharan 
Africa. AIDS 2008;22:1897–908. doi:10.1097/QAD.0b013e32830007cd 
PMID:18784453
33. Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, Odeke E et al. Good 
adherence to HAART and improved survival in a community HIV/AIDS 
treatment and care programme: the experience of The AIDS Support 
Organization (TASO), Kampala, Uganda. BMC Health Serv Res 2008;8:241. 
doi:10.1186/1472-6963-8-241 PMID:19021908
34. Dalal RP, MacPhail C, Mqhayi M, Wing J, Feldman C, Chersich MF et al. 
Characteristics and outcomes of adult patients lost to follow-up at an 
antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir 
Immune Defic Syndr 2008;47:101–7. doi:10.1097/QAI.0b013e31815b833a 
PMID:17971708
35. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ et al. True 
outcomes for patients on antiretroviral therapy who are “lost to follow-
up” in Malawi. Bull World Health Organ 2007;85:550–4. doi:10.2471/
BLT.06.037739 PMID:17768504
36. Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de With TF, 
Schuurman R. The status of HIV-1 resistance to antiretroviral drugs in sub-
Saharan Africa. Antivir Ther 2008;13:625–39. PMID:18771046
37. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG et al. 
Conservation of first-line antiretroviral treatment regimen where therapeutic 
options are limited. Antivir Ther 2007;12:83–8. PMID:17503751
